Lonza’s Epibase™ In Silico platform is a patented T cell epitope screening tool for the identification of potential epitopes in biotherapeutic protein and antibody targets.  The tool is driven by sequence information, structural bioinformatics, and experimental data.  The Epibase™ In Silico tool uses structural characteristics of the HLA receptor along with experimentally determined binding affinities to predict potential peptide/HLA binding, a condition necessary for T cell activation.

The Epibase™ In Silico tool supports lead candidate selection, ranking, optimization, and design for the development of biotherapeutic proteins and antibodies with reduced immunogenicity risk.

 

Help Increase Chance of Clinical Success

  • Global population coverage, greater than 99% coverage, including 85 HLA Class II allotypes
  • Analysis includes binding affinity, promiscuity and frequency of allotypes
  • High accuracy of prediction based on in vitro correlations
  • Reduce immune response with in silico-guided engineering of epitope sequences
  • Can link in silico results with Epibase™ In Vitro assays for confirmation of promising candidates

 

Save Time and Money in Development

  • Lonza's scientific experts perform the work, analyze results and provide consultation on data interpretation
  • Rapidly assess biotherapeutic proteins with a high throughput process
  • Reduce labor using in silico screening to identify top peptides as compared to in vitro screening of whole protein
  • Focus R&D resources on a smaller number of protein targets with the greatest chance of success early in development